Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q96GP6
UPID:
SREC2_HUMAN
Alternative names:
SRECRP-1; Scavenger receptor expressed by endothelial cells 2 protein
Alternative UPACC:
Q96GP6; E5RFB8; Q58A83; Q8IXF3; Q9BW74
Background:
Scavenger receptor class F member 2 (SRECRP-1, Scavenger receptor expressed by endothelial cells 2 protein) is identified as a probable adhesion protein facilitating both homophilic and heterophilic interactions. Unlike SCARF1, its efficiency in mediating the binding and degradation of acetylated low-density lipoprotein (Ac-LDL) is limited. This protein plays a pivotal role in cellular processes through its receptor functions.
Therapeutic significance:
Van den Ende-Gupta syndrome, a condition marked by distinct craniofacial and skeletal abnormalities, is linked to mutations affecting this protein. Understanding the role of Scavenger receptor class F member 2 could open doors to potential therapeutic strategies for this rare syndrome, highlighting its clinical importance.